فحص مستوى البروتين (Activation induced-cytidine Deaminase ) عند مرضى سرطان الرئة
Expression of Activation Induced Cytidine Deaminase (AID) In Lung Cancer
كوثر علي صالح قضماني
kawthar ali saleh qadamani
MetadataShow full item record
Lung cancer (LC) is the most common cancer worldwide, affecting over a million people every year. It is the leading cause of cancer-related death in the world, and the diagnosis of this disease is usually associated with poor prognosis. In Palestine, according to the Palestinian Cancer Registry (PCR), lung cancer has been considered the fourth common cancer morbidity in the general population, and considered the first common cancer mortality in the general population. Activation induced cytidine deaminase (AID), a member of the cytidine deaminase family, is expressed in activated B cells and is involved in antibody diversification by inducing the mutations of immunoglobulin genes. The role of AID in immune response is essential for somatic hypermutation & class switch recombination in B lymphocytes. Although the primary and physiologically relevant targets for AID are immunoglobulins, AID has been shown to attack non-immunoglobulin genes and induce mutations broadly throughout the genome. This property of AID; acting as a DNA mutator, is considered a double edge sword in cellular metabolism. Several studies have shown that AID expression is associated with non-Hodgkin lymphoma and follicular lymphoma as well as non lymphoid cancers such as gastric cancer, hepatocellular carcinoma, and ulcerative colitis-associated carcinoma. The aim of this study is to investigate the expression levels of AID protein in several types of LC in Palestinian patients, to check if AID is aberrantly expressed in these types. To achieve this aim, parrafin blocks of 63 LC cases with their clinico-pathological data, werecollected retrospectively (from 2000-2011) from patients' medical files from the pathology department of Al-Maqassed hospital. And the expression levels of AID were examined in all these cases by immunohistochemistry (IHC) analysis. Aberrant AID protein expression was detected in 22.2% (13 of 58) of the LC cases. The results showed that AID protein was expressed in 18% (10 of 50) of non-small cell lung carcinoma (NSCLC) and 100% (3 of 3) of small cell lung carcinoma (SCLC). Moreover 23% (7 of 31) of squamous cell carcinoma and 13% (3 of 24) of adenocarcinoma express AID protein. No correlation was detected between AID protein expression and clinicpathological data of the patients such as gender, age, LC type, tumor grade. In conclusion, examination of AID protein expression in LC revealed aberrant expression of AID protein in a subset of LC Palestinian patients.